Flt-1 Inhibitors
Santa Cruz Biotechnology now offers a broad range of Flt-1 Inhibitors. Flt-1 (also designated VEGF-R1), Flk-1 (also designated VEGF-R2 or KDR) and Flt-4 (also designated VEGF-R3) are three cell membrane receptor tyrosine kinases, putatively involved in the growth of endothelial cells. Flt-1 is thought to modulate Flk-1 signaling. Flt-1 Inhibitors offered by Santa Cruz inhibit Flt-1 and, in some cases, other cell mitogenesis and cell migration related proteins. View detailed Flt-1 Inhibitor specifications, including Flt-1 Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.
Items 21 to 23 of 23 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brivanib | 649735-46-6 | sc-364447 sc-364447A | 5 mg 10 mg | $263.00 $370.00 | ||
Brivanib acts as a potent inhibitor of the Flt-1 receptor, showcasing a unique binding affinity that alters the receptor's conformational landscape. Its molecular architecture facilitates specific electrostatic interactions, enhancing selectivity. The compound exhibits a notable impact on downstream signaling pathways, with a kinetic profile that supports prolonged engagement with the receptor. This behavior underscores its distinctive role in modulating cellular responses through targeted molecular interactions. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib is a direct inhibitor of Flt-1 and other receptor tyrosine kinases. Functioning as a tyrosine kinase inhibitor, Vandetanib interferes with the kinase activity of Flt-1, preventing the activation of downstream signaling pathways. This direct inhibition of Flt-1 by Vandetanib serves to modulate cellular responses associated with Flt-1 activation, offering a targeted approach to controlling Flt-1-mediated biological effects. | ||||||
AEE 788 | 497839-62-0 | sc-480425 | 10 mg | $4665.00 | ||
AEE788 is a direct inhibitor of Flt-1, acting as a multi-kinase inhibitor. By inhibiting the tyrosine kinase activity of Flt-1, AEE788 disrupts the downstream signaling pathways associated with Flt-1. This direct inhibition of Flt-1 contributes to the overall suppression of cellular processes driven by Flt-1 activation, providing a targeted approach to controlling Flt-1-mediated responses. | ||||||